Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients (original) (raw)
Pasare C, Medzhitov R (2005) Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 560:11–18 ArticlePubMedCAS Google Scholar
Nembrini C, Abel B, Kopf M, Marsland BJ (2006) Strong TCR signaling, TLR ligands, and cytokines redundancies ensure robust development of type 1 effector T cells. J Immunol 176:7180–7188 PubMedCAS Google Scholar
Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune response. Nat Immunol 5:987–995 ArticlePubMedCAS Google Scholar
Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ, de Vries IJ (2010) Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 59:1573–1582 ArticlePubMedCAS Google Scholar
Frankenberger B, Schendel DJ (2012) Third generation dendritic cell vaccines for tumor immunotherapy. Eur J Cell Biol 91:53–58 ArticlePubMedCAS Google Scholar
Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13:552–559 ArticlePubMedCAS Google Scholar
Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M (2004) Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50:722–733 ArticlePubMed Google Scholar
Adams S (2009) Toll-like receptor agonists in cancer therapy. Immunother 1:949–964 ArticleCAS Google Scholar
Re F, Strominger JL (2001) Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 276:37692–37699 ArticlePubMedCAS Google Scholar
Srivastava P (2002) Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2:185–194 ArticlePubMedCAS Google Scholar
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059 ArticlePubMedCAS Google Scholar
Schröder NWJ, Schumann RR (2005) Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 5:156–164 PubMed Google Scholar
Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M, Izagirre N et al (2007) TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci USA 104:16645–16650 ArticlePubMed Google Scholar
Santos JL, Lera L, Pérez-Bravo F, Albala C (2006) Adiposity and bone mineral density of Chilean elderly women in relation to toll-like receptor 4 gene polymorphisms. Ann Hum Biol 33:585–592 ArticlePubMedCAS Google Scholar
Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M et al (2000) TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Gen 25:187–191 ArticleCAS Google Scholar
Tal G, Mandelberg A, Dalal I, Cesar K, Somekh E, Tal A et al (2004) Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 189:2057–2063 ArticlePubMedCAS Google Scholar
Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B et al (2008) Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol 154:360–364 ArticlePubMedCAS Google Scholar
Kutikhin AG (2011) Impact of Toll-like receptor 4 polymorphisms on risk of cancer. Hum Immunol 72:193–206 ArticlePubMedCAS Google Scholar
Bergmann C, Bachmann HS, Bankfalvi A, Lotfi R, Pütter C, Wild CA et al (2011) Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med 9:139 ArticlePubMedCAS Google Scholar
Gast A, Bermejo JL, Claus R, Brandt A, Weires M, Weber A et al (2011) Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival. PLoS ONE 6:e24370 ArticlePubMedCAS Google Scholar
Escobar A, López MN, Serrano A, Ramírez M, Pérez C, Aguirre A et al (2005) Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 142:555–568 PubMedCAS Google Scholar
López MN, Pereda C, Segal G, Muñoz L, Aguilera R, González FE et al (2009) Prolonged survival of dendritic cell–vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor β-expressing T cells. J Clin Oncol 27:945–952 ArticlePubMed Google Scholar
Aguilera R, Saffie C, Tittarelli A, González FE, Ramírez M, Reyes D et al (2011) Heat-shock induction of tumor-derived danger signals mediate rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res 17:2474–2483 ArticlePubMedCAS Google Scholar
Costes SV, Daelemans D, Cho EH, Dobbin Z, Pavlakis G, Lockett S (2004) Automatic and quantitative measurement of protein–protein co localization in live cells. Biophys J 86:3993–4003 ArticlePubMedCAS Google Scholar
Chomczynski P, Mackey K, Drews R, Wilfinger W (1997) DNAzol: a reagent for the rapid isolation of genomic DNA. Biotechniques 22:550–553 PubMedCAS Google Scholar
Figueroa C, Peralta A, Herrera L, Castro P, Gutiérrez A, Valenzuela J et al (2006) NOD2/CARD15 and Toll-like 4 receptor gene polymorphism in Chilean patients with inflammatory bowel disease. Eur Cytokine Netw 17:125–130 PubMedCAS Google Scholar
Mendoza-Naranjo A, Sáez PJ, Johansson CC, Ramírez M, Mandakovic D, Pereda C et al (2007) Functional gap junctions facilitate melanoma antigen transfer and cross-presentation between human dendritic cells. J Immunol 178:6949–6957 PubMedCAS Google Scholar
van der Graaf C, Kullberg BJ, Joosten L, Verver-Jansen T, Jacobs L, Van der Meer JW, Netea MG (2005) Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine 30:264–268 ArticlePubMed Google Scholar
Andrews DM, Maraskovsky E, Smyth MJ (2008) Cancer vaccines for established cancer: how to make them better? Immunol Rev 222:242–255 ArticlePubMedCAS Google Scholar
Zaloudik J, Vagunda V, Drahokoupilova M, Janakova L, Talac R, Kalabis J, Sheard M (1997) Biomarkers for predicting response to regional chemo-immunotherapy in liver metastases from colorectal carcinoma. Int J Immunopharmacol 19:481–485 ArticlePubMedCAS Google Scholar
Hicklin DJ, Marincola FM, Ferrone S (1999) HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5:178–186 ArticlePubMedCAS Google Scholar
Ahirwar D, Kesarwani P, Manchanda PK, Mandhani A, Mittal RD (2008) Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer. Cancer Genet Cytogenet 184:1–8 ArticlePubMedCAS Google Scholar
Jung ID, Jeong SK, Lee CM, Noh KT, Heo DR, Shin YK et al (2011) Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist. Cancer Res 71:2858–2870 ArticlePubMedCAS Google Scholar
Riddell JR, Wang XY, Minderman H, Gollnick SO (2010) Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4. J Immunol 184:1022–1030 ArticlePubMedCAS Google Scholar
Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ et al (2006) HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26:174–179 ArticlePubMedCAS Google Scholar
El Mezayen R, El Gazzar M, Seeds MC, McCall CE, Dreskin SC, Nicolls MR (2007) Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol Lett 111:36–44 ArticlePubMed Google Scholar
Casanova JL, Abel L, Quintana-Murci L (2011) Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 29:447–491 ArticlePubMedCAS Google Scholar
Loeffler J, Ok M, Morton OC, Mezger M, Einsele H (2010) Genetic polymorphisms in the cytokine and chemokine system: their possible importance in allogeneic stem cell transplantation. Curr Top Microbiol Immunol 341:83–96 ArticlePubMedCAS Google Scholar
Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R (2004) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 22:4717–4724 ArticlePubMedCAS Google Scholar
Ugurel S, Schrama D, Keller G, Schadendorf D, Bröcker EB, Houben R et al (2008) Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother 57:685–691 ArticlePubMedCAS Google Scholar
Tze LE, Horikawa K, Domaschenz H, Howard DR, Roots CM, Rigby RJ et al (2011) CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10–driven MARCH1-mediated ubiquitination and degradation. J Exp Med 208:149–165 ArticlePubMedCAS Google Scholar
Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420 ArticlePubMedCAS Google Scholar
Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29:482–491 ArticlePubMedCAS Google Scholar
Baxevanis CN, Perez SA, Papamichail M (2009) Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 58:317–324 ArticlePubMed Google Scholar